145 related articles for article (PubMed ID: 24102752)
1. Pirfenidone: a potential new therapy for restrictive allograft syndrome?
Vos R; Verleden SE; Ruttens D; Vandermeulen E; Yserbyt J; Dupont LJ; Van Raemdonck DE; De Raedt N; Gheysens O; De Jong PA; Verleden GM; Vanaudenaerde BM
Am J Transplant; 2013 Nov; 13(11):3035-40. PubMed ID: 24102752
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series.
Vos R; Wuyts WA; Gheysens O; Goffin KE; Schaevers V; Verleden SE; Van Herck A; Sacreas A; Heigl T; McDonough JE; Yserbyt J; Godinas L; Dupont LJ; Neyrinck AP; Van Raemdonck DE; Verbeken EK; Vanaudenaerde BM; Verleden GM
Am J Transplant; 2018 Dec; 18(12):3045-3059. PubMed ID: 30019840
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.
Liu H; Drew P; Gaugler AC; Cheng Y; Visner GA
Am J Transplant; 2005 Jun; 5(6):1256-63. PubMed ID: 15888029
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
Dosanjh A
Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
Dosanjh A
Transplant Proc; 2007 Sep; 39(7):2153-6. PubMed ID: 17889122
[TBL] [Abstract][Full Text] [Related]
6. Role of 18F-FDG PET/CT in Restrictive Allograft Syndrome After Lung Transplantation.
Verleden SE; Gheysens O; Goffin KE; Vanaudenaerde BM; Verbeken EK; Weynand B; Van Raemdonck DE; Verleden GM; Vos R
Transplantation; 2019 Apr; 103(4):823-831. PubMed ID: 30086092
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.
Liu H; Drew P; Cheng Y; Visner GA
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):852-8. PubMed ID: 16153939
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone in chronic lung allograft dysfunction: a single cohort study.
Bennett D; Lanzarone N; Fossi A; Perillo F; De Vita E; Luzzi L; Paladini P; Bargagli E; Sestini P; Rottoli P
Panminerva Med; 2020 Sep; 62(3):143-149. PubMed ID: 32192319
[TBL] [Abstract][Full Text] [Related]
9. Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone.
Reinholz M; Eder I; Przybilla B; Schauber J; Wollenberg A; Wulffen W; Goldscheider I; Varga R; Ruzicka T; Schaumann A; Ruëff F
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):370-1. PubMed ID: 25327710
[No Abstract] [Full Text] [Related]
10. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone: a potential therapy for progressive lung allograft dysfunction?
Ihle F; von Wulffen W; Neurohr C
J Heart Lung Transplant; 2013 May; 32(5):574-5. PubMed ID: 23453574
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
[TBL] [Abstract][Full Text] [Related]
13. Kaposi sarcoma after bilateral lung transplantation.
Martinez S; McAdams HP; Youens KE
J Thorac Imaging; 2008 Feb; 23(1):50-3. PubMed ID: 18347522
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation.
Veit T; Leuschner G; Sisic A; Ceelen F; Munker D; Schmitzer M; Weig T; Michel S; Schneider C; Meiser B; Crispin A; Neurohr C; Behr J; Milger K; Kneidinger N
Am J Transplant; 2019 Aug; 19(8):2358-2365. PubMed ID: 30942945
[TBL] [Abstract][Full Text] [Related]
15. Acoustic evaluation of pirfenidone on patients with combined pulmonary fibrosis emphysema syndrome.
Charleston-Villalobos S; Castaneda-Villa N; Gonzalez-Camarena R; Mejia-Avila M; Mateos-Toledo H; Aljama-Corrales T
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():3175-3178. PubMed ID: 28268982
[TBL] [Abstract][Full Text] [Related]
16. A combined therapeutic approach in progressive idiopathic pulmonary fibrosis-pirfenidone as bridge therapy for ex vivo lung transplantation: a case report.
Paone G; Sebastiani A; Ialleni E; Diso D; Rose D; Quagliarini F; Ialongo P; Peruzzi M; Venuta F; Frati G
Transplant Proc; 2015 Apr; 47(3):855-7. PubMed ID: 25891747
[TBL] [Abstract][Full Text] [Related]
17. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Antoniu SA
Expert Opin Investig Drugs; 2006 Jul; 15(7):823-8. PubMed ID: 16787145
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
20. Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis.
Tanaka KI; Azuma A; Miyazaki Y; Sato K; Mizushima T
Chest; 2012 Oct; 142(4):1011-1019. PubMed ID: 22459774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
